NCT00238407View on ClinicalTrials.gov

Docetaxel, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced Esophageal Cancer That Cannot Be Removed By Surgery

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

March 31, 2004

Primary Completion Date

February 29, 2008

Study Completion Date

August 31, 2010

Conditions
Esophageal Cancer
Interventions
DRUG

Docetaxel and Cisplatin

Patients receive docetaxel IV over 30-60 minutes and cisplatin IV over 1 hour on days 1, 22, 43, 50, 57, 64, and 71.

RADIATION

Radiotherapy

Beginning on day 43 (week 7) of chemotherapy, patients undergo radiotherapy once daily, 5 days a week, for 7 weeks.

Trial Locations (10)

3600

Regionalspital, Thun

CH-5001

Hirslanden Klinik Aarau, Aarau

CH-4016

Saint Claraspital AG, Basel

CH-4031

Universitaetsspital-Basel, Basel

CH-3010

Inselspital Bern, Bern

CH-4101

Kantonsspital Bruderholz, Bruderholz

CH-7000

Kantonsspital Graubuenden, Chur

CH-4410

Kantonsspital, Liestal

CH-9007

Kantonsspital - St. Gallen, Sankt Gallen

CH-8063

City Hospital Triemli, Zurich

All Listed Sponsors
lead

Swiss Cancer Institute

OTHER

NCT00238407 - Docetaxel, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced Esophageal Cancer That Cannot Be Removed By Surgery | Biotech Hunter | Biotech Hunter